Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Kevin G Pollock

principal epidemiologist for the Scottish HPV surveillance programme and Honorary Lecturer in Infection, Immunity & Inflammation at the University of Glasgow

Contact Info

Email:
kevin.pollock@nhs.net

Recent stories

  • Teenager gets an HPV vaccine injection

    The impact of the human papillomavirus vaccine in Scotland: a changing landscapeSubscription

    8 MAR 2017

    In the UK, cervical cancer is the second most common cancer in women aged under 35 years. Human papillomavirus (HPV) types 16 and 18 (both high risk) are necessary precipitants in at least 70% of cervical cancers but may contribute to more than 80% of cervical cancers in Scotland. Both the prophylactic bivalent (Cervarix; GlaxoSmithKline) and quadrivalent (Gardasil; Merck) vaccines prevent infection with HPV types 16 and 18, and have been shown to induce avid and sustained neutralising antib

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.